AstraZeneca's "Survivors Have Heart" campaign includes meet and greets with Bob Harper, former host of "The Biggest Loser," who has appeared in commercials for the company's anti-coagulant drug Brilinta. A website with survivor stories and a Facebook community are also part of the awareness campaign.
The FDA designated orphan drug status to NuCana's Acelarin, which is indicated to treat biliary tract cancer. In a Phase Ib study, several patients achieved significant reductions in their tumor volume with Acelarin plus cisplatin treatment, and the response rate was doubled of that expected with standard care.
Gilead Sciences and AbCellera agreed to work together to develop therapies for infectious disease using the latter's expertise in single-cell screening of natural immune sources to generate antibody panels for evaluation. Under the terms of the deal, AbCellera will get upfront and research payments plus milestone payments.
Experts from the European Conference on Infections in Leukemia have issued revised clinical practice guidelines on the use of the drug letermovir to prevent cytomegalovirus in adults who will undergo allogeneic hematopoietic stem cell transplant. The updated recommendations were published in the journal The Lancet Infectious Diseases.
Aucta Pharmaceuticals has granted Eton Pharmaceuticals US rights to ET-105, an oral liquid formulation of lamotrigine being developed as an adjunctive treatment for epilepsy patients with partial seizures. Under the terms of the deal, Aucta will get up to $5 million and $18 million licensing and commercial milestones, respectively.
The executive order signed by President Donald Trump earlier this week regarding biotech agriculture will open the door to the creation of a regulatory framework for the use of biotechnology in livestock, according to the American Farm Bureau Federation's congressional relations director, Andrew Walmsley.
A letter sent to Environmental Protection Agency assistant administrator Bill Wehrum by member companies of the Advanced Biofuels Association and the Coalition to Address Removal of Regulatory Impediments urges the agency to remove unnecessary regulatory burdens for the production of advanced biofuels under the proposed Regulatory Enhancement Growth Support rule. The letter requested the agency to allow use of biointermediates in renewable fuel production and co-processing pathways to generate cellulosic D3 and D7 renewable identification numbers, and to approve alternative test procedures to account for the number of RINs created.
Stryker has announced research, development and innovation investments worth around $225 million in three of its Irish facilities. The company's instruments innovation center, AMagine Institute and neurovascular business will see the investments.
Orchestra BioMed and Tokyo-based Terumo have teamed up on the development and commercialization of Orchestra's Virtue sirolimus-eluting balloon in peripheral cardiovascular and coronary interventions. Terms of the agreement include the payment of $30 million upfront and a $5 million equity commitment plus potential milestone payments from Terumo to Orchestra.
Zimmer Biomet has tapped orthopedic surgeon Andrew Freiberg to serve as its chief medical officer, a newly created position in the company. Freiberg, an adult reconstructive surgery expert with a focus on hip and knee arthroplasty, has led Massachusetts General Hospital's hip and knee service for more than two decades.
- Page 1